Robeco Institutional Asset Management B.V. Has $2.94 Million Stake in Moderna, Inc. (NASDAQ:MRNA)

Robeco Institutional Asset Management B.V. cut its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 51.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 44,011 shares of the company's stock after selling 46,337 shares during the period. Robeco Institutional Asset Management B.V.'s holdings in Moderna were worth $2,941,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Ashton Thomas Private Wealth LLC bought a new stake in Moderna during the 2nd quarter worth about $26,000. Cedar Wealth Management LLC lifted its stake in shares of Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company's stock valued at $31,000 after purchasing an additional 90 shares during the period. Family Firm Inc. acquired a new position in shares of Moderna in the 2nd quarter valued at $33,000. Bank & Trust Co bought a new position in shares of Moderna in the 2nd quarter worth $36,000. Finally, Hanseatic Management Services Inc. acquired a new stake in shares of Moderna during the second quarter worth $48,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on MRNA shares. Piper Sandler reduced their target price on Moderna from $157.00 to $115.00 and set an "overweight" rating on the stock in a report on Friday, September 13th. Bank of America cut their price target on shares of Moderna from $130.00 to $110.00 and set a "neutral" rating on the stock in a research report on Friday, September 13th. Jefferies Financial Group decreased their price objective on shares of Moderna from $65.00 to $55.00 and set a "hold" rating for the company in a report on Tuesday, October 15th. Sanford C. Bernstein assumed coverage on shares of Moderna in a report on Thursday, October 17th. They issued a "market perform" rating and a $55.00 target price on the stock. Finally, Hsbc Global Res raised shares of Moderna from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 28th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $93.18.

Moderna Price Performance

Shares of MRNA stock traded down $3.45 on Friday, reaching $46.83. The stock had a trading volume of 13,561,538 shares, compared to its average volume of 5,571,917. Moderna, Inc. has a 12 month low of $46.57 and a 12 month high of $170.47. The firm's 50-day moving average is $61.85 and its two-hundred day moving average is $99.09. The company has a quick ratio of 3.92, a current ratio of 4.39 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company's revenue was up 3.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.39) earnings per share. On average, equities research analysts predict that Moderna, Inc. will post -9.89 earnings per share for the current year.

Insider Transactions at Moderna

In other news, CFO James M. Mock sold 715 shares of the company's stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares of the company's stock, valued at approximately $571,440.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Moderna news, CFO James M. Mock sold 715 shares of the firm's stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO James M. Mock sold 1,321 shares of the company's stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares of the company's stock, valued at $682,754. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,184 shares of company stock worth $238,531 over the last quarter. Company insiders own 15.70% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.